Jonathan E. Rosenberg
A bladder and urothelial cancer oncologist whose clinical trial work includes the case of an exceptional responder to everolimus with activating MTOR mutations.
Chief, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center (since 2018) · Dana-Farber/Brigham and Women's Cancer Center (until 2012) · MD, Harvard Medical School
Portrait: Memorial Sloan Kettering Cancer Center
Jonathan Rosenberg is a medical oncologist who treats bladder and other urinary tract cancers. Since 2018 he has been Chief of the Genitourinary Oncology Service at Memorial Sloan Kettering Cancer Center in New York. Before joining MSK in 2012 he directed the Bladder Cancer Center at Dana-Farber/Brigham and Women's Cancer Center in Boston.
The 2014 study in this Atlas began with one unusual patient. In a phase I trial of everolimus (an mTOR inhibitor) plus pazopanib, a person with advanced bladder cancer had a complete response lasting 14 months. Sequencing the tumor found two mutations in the MTOR gene itself, and lab experiments showed both made mTOR more active, which may explain why the drug worked so well in this person.
This is a single-patient observation. It suggests that mTOR pathway mutations could help pick patients for mTOR-targeted therapy, but it does not prove that they predict response in general.
Milestones in the Atlas
A selection, not a full bibliography: only papers that meet the Atlas inclusion criteria.
| Year | Evidence | Study |
|---|---|---|
| 2014 | H | Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib WAG2014 Senior author on the report of an exceptional responder to everolimus plus pazopanib whose tumor carried two activating MTOR mutations; a hypothesis-generating single case. |
Co-authors in the Atlas 3
People with a profile here who share at least one study with Jonathan E. Rosenberg.
ShowHide
- Brian C. Grabiner Catalogued cancer-associated MTOR mutations and showed that many of them hyperactivate the kinase and can predict sensitivity to rapamycin; he also contributed to the discovery of GATOR1
- David M. Sabatini Identified mTOR (as RAFT1) in 1994. His lab then mapped much of the machinery around it: raptor and rictor at the core of mTORC1 and mTORC2, the Rag–Ragulator system that docks mTORC1 on the lysosome, and the sensors that detect leucine, arginine and SAM
- Nikhil Wagle Medical oncologist and cancer genomics researcher at Dana-Farber who studies why some patients respond exceptionally well to targeted drugs, including a patient whose tumour carried two activating MTOR mutations
Every researcher with a profile →
Thank you. That helps us know which pages have been read by someone who knows the work.
Thank you. We will check it and correct the page.
Thank you. Your answer was counted anonymously.